NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,114 | +3.5% | 38,808 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $22,322 | -29.0% | 38,808 | -13.2% | 0.00% | -40.0% |
| Q1 2023 | $31,425 | -66.1% | 44,708 | +9.0% | 0.01% | -70.6% |
| Q4 2022 | $92,678 | -29.3% | 41,008 | 0.0% | 0.02% | -32.0% |
| Q3 2022 | $131,000 | -47.0% | 41,008 | -27.9% | 0.02% | -34.2% |
| Q1 2022 | $247,000 | -84.2% | 56,863 | -34.7% | 0.04% | -92.3% |
| Q1 2020 | $1,568,000 | -32.0% | 87,045 | -18.5% | 0.49% | -34.6% |
| Q4 2019 | $2,306,000 | – | 106,850 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |